BLASOLUTIONINJECTION
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ARMLUPEG (pegfilgrastim-unne) by Lupin Ltd. is colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARMLUPEG (pegfilgrastim-unne) is a biosimilar granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation and differentiation of hematopoietic cells to increase neutrophil production. It is indicated for patients undergoing chemotherapy to reduce the incidence of infection-related complications and chemotherapy-induced neutropenia. The drug works by binding to specific cell surface receptors on hematopoietic cells, triggering proliferation, differentiation, and functional activation.
Launch
Early-stage launch with moderate competitive pressure (30%) suggests a growing team focused on market penetration and establishing clinical relationships in oncology.
Mechanism of Action
colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARMLUPEG launch offers entry and mid-level career opportunities in a high-volume oncology support product with established market demand and reimbursement. Success in this role depends on competitive positioning, payer negotiation, and clinical relationship-building in a crowded biosimilar space.
Brand Manager
Worked on ARMLUPEG at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.